Clinical Trial Update: Dose-ranging Study of Dentoxol® Mouthrinse for Managing Oral Symptoms in People With Epidermolysis Bullosa. [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging study evaluating Dentoxol Mouthrinse for oral symptoms in Epidermolysis Bullosa with oral ulcers; status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Oral Ulcers

Drugs mentioned

• Dentoxol

Snippet

Sponsor: University of Chile | Conditions: Epidermolysis Bullosa, Oral Ulcer | Phase 2 | Status: UNKNOWN